<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172292">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853307</url>
  </required_header>
  <id_info>
    <org_study_id>C14006</org_study_id>
    <nct_id>NCT00853307</nct_id>
  </id_info>
  <brief_title>MLN8237 for Treatment of Patients With Ovarian, Fallopian Tube, or Peritoneal Carcinoma</brief_title>
  <official_title>A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients With Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, single-arm, phase 2 study of MLN8237 in the treatment of
      patients with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube,
      or primary peritoneal carcinomas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined objective response rate, defined as complete response + partial response by Response Evaluation Criteria in Solid Tumors criteria or response by CA 125 criteria</measure>
    <time_frame>CT or MRI every 2 cycles (6 weeks) to 12 months until progressive disease</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival, Duration Of Response, Time To Progression, and clinical benefit rate</measure>
    <time_frame>CT or MRI every 2 cycles up to 12 months until progressive disease is documented. Patients who discontinue study drug before progressive disease will be assessed at Follow-Up visits once every 12 weeks up to 12 months, until progressive disease or other</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, serious adverse events, assessments of clinical laboratory values, and vital signs measurements</measure>
    <time_frame>Clinical exam prior to every cycle (21 days); safety labs weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MLN8237</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN8237</intervention_name>
    <description>MLN8237 will be given by mouth in a dosage of 50 mg twice a day for 7 Days (Days 1-7) of each 21-day treatment cycle.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients 18 years or older

          2. Histologically or cytologically confirmed epithelial ovarian, fallopian tube, or
             primary peritoneal carcinoma.

          3. Eastern Cooperative Oncology Group performance status 0 or 1

          4. Postmenopausal at least 1 year, OR

               -  Surgically sterile, OR

               -  If childbearing potential, agree to 2 effective methods of nonhormonal
                  contraception, or agree to completely abstain from heterosexual intercourse

          5. Able to provide written informed consent.

          6. Within 7 days before study:

               -  Absolute neutrophils (ANC) ≥ 1,500/μL

               -  Platelets ≥100,000/ μL

               -  Total bilirubin must be &lt; 1.5 times upper limit of the normal (ULN)

               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) must be ≤ 2.5
                  times the ULN. AST and ALT may be elevated up to 5 times the ULN if ascribed to
                  metastatic liver disease.

               -  Creatinine clearance ≥ 30 mL/minute

          7. Platinum-refractory or -resistant disease

          8. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) OR CA 125
             level of &gt; 40 units/mL AND clinical evidence disease

          9. Recovered from effects of prior therapy

        Exclusion Criteria:

          1. Pregnant or lactating

          2. Serious illness that could interfere with protocol completion

          3. Investigational treatment 28 days prior to first dose.

          4. Maximum 4 prior systemic therapies: 2 platinum-based, 1 nonplatinum cytotoxic, 1
             biological

          5. Known Central Nervous System metastases

          6. Prior allogeneic bone marrow or organ transplantation

          7. Radiotherapy within 21 days prior to first dose

          8. Radiotherapy to &gt; 25% bone marrow

          9. Major surgery, infection requiring systemic antibiotic therapy within 14 days prior
             to first dose

         10. Inability to swallow orally administered medication

         11. Diagnosis or treatment of another malignancy within 2 years preceding first dose of
             study drug except nonmelanoma skin cancer or in situ malignancy completely resected

         12. Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
             hepatitis C.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 15, 2013</lastchanged_date>
  <firstreceived_date>February 26, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>January 27, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
